FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2078249980> ?p ?o ?g. }

• W2078249980 endingPage "817" @default.
• W2078249980 startingPage "810" @default.
• W2078249980 abstract "The primary aim of this trial was to assess the rate of pathologic complete responses (pCR) of doxorubicin/cyclophosphamide (AC) followed by bevacizumab/docetaxel (BT), as neoadjuvant therapy for breast cancer (BC). Furthermore, the association between biomarkers and the pCR was explored. Patients with HER-negative operable stage II–III BC ≥2 cm were enrolled. Four cycles of AC (A 60 mg/m2 and C 600 mg/m2, every 3 weeks) followed by 4 cycles of BT (B 15 mg/kg and T 75 mg/m2, every 3 weeks), were planned. A core-biopsy was performed for biological markers assessment. Seventy-two women were included. Forty-three (63 %) patients were hormone receptor-positive. Sixty-four (89 %) completed the planned treatment, and 66 evaluable patients underwent surgery (92 %): a pCR was achieved in 16 of them (24, 95 % CI 15–36 %). pCR was significantly higher in tumors hormone receptor-negative, and in those with Angiotensin II type 1 receptor (AGTR1) protein overexpression. The overall clinical response rate was 86 % (95 % CI 76–93 %), including 42 complete responses. No unexpected toxicities or treatment-related deaths were observed. This regimen showed a remarkable clinical and pathological activity: the suggested relation between pCR and AGTR1 overexpression should be confirmed in larger trials." @default.
• W2078249980 created "2016-06-24" @default.
• W2078249980 creator A5006303373 @default.
• W2078249980 creator A5026659575 @default.
• W2078249980 creator A5037512953 @default.
• W2078249980 creator A5040158829 @default.
• W2078249980 creator A5042675542 @default.
• W2078249980 creator A5064901053 @default.
• W2078249980 creator A5067802897 @default.
• W2078249980 creator A5073706207 @default.
• W2078249980 creator A5074210261 @default.
• W2078249980 creator A5083318491 @default.
• W2078249980 creator A5085797367 @default.
• W2078249980 creator A5086354022 @default.
• W2078249980 creator A5091506554 @default.
• W2078249980 date "2013-02-09" @default.
• W2078249980 modified "2023-10-18" @default.
• W2078249980 title "Bevacizumab plus preoperative chemotherapy in operable HER2 negative breast cancer: biomarkers and pathologic response" @default.
• W2078249980 cites W1754020298 @default.
• W2078249980 cites W1970210435 @default.
• W2078249980 cites W1989343097 @default.
• W2078249980 cites W1990185598 @default.
• W2078249980 cites W2003029412 @default.
• W2078249980 cites W2020724013 @default.
• W2078249980 cites W2029409133 @default.
• W2078249980 cites W2049051984 @default.
• W2078249980 cites W2055679225 @default.
• W2078249980 cites W2059168692 @default.
• W2078249980 cites W2061094294 @default.
• W2078249980 cites W2084740377 @default.
• W2078249980 cites W2095704084 @default.
• W2078249980 cites W2096910745 @default.
• W2078249980 cites W2107631501 @default.
• W2078249980 cites W2109462843 @default.
• W2078249980 cites W2117188579 @default.
• W2078249980 cites W2118605519 @default.
• W2078249980 cites W2121049748 @default.
• W2078249980 cites W2122298066 @default.
• W2078249980 cites W2122574381 @default.
• W2078249980 cites W2128822091 @default.
• W2078249980 cites W2139248078 @default.
• W2078249980 cites W2139510434 @default.
• W2078249980 cites W2140654333 @default.
• W2078249980 cites W2153158488 @default.
• W2078249980 cites W2154142993 @default.
• W2078249980 cites W2172164998 @default.
• W2078249980 doi "https://doi.org/10.1007/s12094-013-1006-4" @default.
• W2078249980 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3776259" @default.
• W2078249980 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23397155" @default.
• W2078249980 hasPublicationYear "2013" @default.
• W2078249980 type Work @default.
• W2078249980 sameAs 2078249980 @default.
• W2078249980 citedByCount "11" @default.
• W2078249980 countsByYear W20782499802013 @default.
• W2078249980 countsByYear W20782499802014 @default.
• W2078249980 countsByYear W20782499802015 @default.
• W2078249980 countsByYear W20782499802016 @default.
• W2078249980 countsByYear W20782499802019 @default.
• W2078249980 countsByYear W20782499802021 @default.
• W2078249980 crossrefType "journal-article" @default.
• W2078249980 hasAuthorship W2078249980A5006303373 @default.
• W2078249980 hasAuthorship W2078249980A5026659575 @default.
• W2078249980 hasAuthorship W2078249980A5037512953 @default.
• W2078249980 hasAuthorship W2078249980A5040158829 @default.
• W2078249980 hasAuthorship W2078249980A5042675542 @default.
• W2078249980 hasAuthorship W2078249980A5064901053 @default.
• W2078249980 hasAuthorship W2078249980A5067802897 @default.
• W2078249980 hasAuthorship W2078249980A5073706207 @default.
• W2078249980 hasAuthorship W2078249980A5074210261 @default.
• W2078249980 hasAuthorship W2078249980A5083318491 @default.
• W2078249980 hasAuthorship W2078249980A5085797367 @default.
• W2078249980 hasAuthorship W2078249980A5086354022 @default.
• W2078249980 hasAuthorship W2078249980A5091506554 @default.
• W2078249980 hasBestOaLocation W20782499801 @default.
• W2078249980 hasConcept C121608353 @default.
• W2078249980 hasConcept C126322002 @default.
• W2078249980 hasConcept C143998085 @default.
• W2078249980 hasConcept C23589133 @default.
• W2078249980 hasConcept C2776694085 @default.
• W2078249980 hasConcept C2776755627 @default.
• W2078249980 hasConcept C2777802072 @default.
• W2078249980 hasConcept C2778292576 @default.
• W2078249980 hasConcept C2781190966 @default.
• W2078249980 hasConcept C2781413609 @default.
• W2078249980 hasConcept C530470458 @default.
• W2078249980 hasConcept C71924100 @default.
• W2078249980 hasConcept C90924648 @default.
• W2078249980 hasConceptScore W2078249980C121608353 @default.
• W2078249980 hasConceptScore W2078249980C126322002 @default.
• W2078249980 hasConceptScore W2078249980C143998085 @default.
• W2078249980 hasConceptScore W2078249980C23589133 @default.
• W2078249980 hasConceptScore W2078249980C2776694085 @default.
• W2078249980 hasConceptScore W2078249980C2776755627 @default.
• W2078249980 hasConceptScore W2078249980C2777802072 @default.
• W2078249980 hasConceptScore W2078249980C2778292576 @default.
• W2078249980 hasConceptScore W2078249980C2781190966 @default.
• W2078249980 hasConceptScore W2078249980C2781413609 @default.
• W2078249980 hasConceptScore W2078249980C530470458 @default.

• next